Phase III retatrutide study demonstrates 30% weight loss. May 22, 2026
Continuation of GLP-1 Receptor Agonist Use in Early Pregnancy Seems Safe WEDNESDAY, June 10, 2026 -- Continuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) into early pregnancy seems not to be associated with the risk for nonlive birth, abnormal fetal growth, or major congenital malformation (MCM), according to a study published online June 9 in the Annals of Internal Medicine
Moran et al., 2005
Essential role for protein kinase C in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat
The GLP-1R and GIPR pathways both converge on beta cell function through incretin signaling, and retatrutide provides a tool to study the amplified incretin response that occurs when both receptors are activated simultaneously
The investigations have shown that MSG has toxic effects on the testicular tissue, causing oligospermia and increasing abnormalities in sperm shape and morphology in Wistar rats [58, 59]